Please login to the form below

Not currently logged in
Email:
Password:

I-Mab

This page shows the latest I-Mab news and features for those working in and with pharma, biotech and healthcare.

AbbVie signs immunotherapy pact with I-Mab worth $2bn

AbbVie signs immunotherapy pact with I-Mab worth $2bn

In addition, I-Mab will receive a milestone payment of $20m based on results from phase 1 studies of the drug. ... If the drug proves effective and wins regulatory approval, AbbVie will also pay I-Mab tiered royalties from low-to-mid teen percentages on

Latest news

  • Morphosys’ Darzalex patent challenge hits a hurdle Morphosys’ Darzalex patent challenge hits a hurdle

    China in the first quarter of this year with the help of partner I-Mab, which licensed rights to the drug in mainland China, Hong Kong, Macau and Taiwan in November

  • Biologics at forefront

    anti-IL 21 MAb (autoimmune/inflammatory disease)   . Preclinical . 181.5. Intercell/GSK Biologicals . patch-based vaccines  .  . ... 5m at the start of phase I studies on the IL-21 MAb, plus royalties on net sales.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Acquisition - company. $600. Boehringer Ingelheim/ AbbVie. BI-655066: anti-IL-23 MAb in Phase III for psoriasis and other autoimmune disorders; and BI-655064: anti-CD-40 MAb in Phase I. ... Acquisition – company. $200. TaiMed/ Theratechnologies.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...